Reimagining Medicine
Company overview
Financial review
2023 priorities
Appendix
STRATEGY
New Novartis expected to continue delivering improved financials
New Novartis expectations (illustrative only)
Sales
% cc, CAGR
+4%
2022
2027
Core Operating Income Margin
(corporate costs absorbed)
-40%+
Incremental benefit
from planned Sandoz spin-off
Free Cash Flow
% of sales
2022
Expected to grow sales, core margin
and FCF (% of sales)
Margin targets include absorbing
corporate costs
Planned Sandoz spin-off will result in
incremental growth for:
2027
◉
Core operating income margin
"
FCF (% of sales)
■
Return on invested capital
Return on Invested Capital
2022
2027+
2022
2027
7 Investor Relations | Q4 2022 Results
Remain committed
to capital allocation priorities,
with growing (CHF) annual dividend
NOVARTIS | Reimagining MedicineView entire presentation